An international collaboration, using data from more than 100,000 women with breast cancer from 58 epidemiological studies worldwide, has found that using menopausal hormone therapy (MHT) is associated with an increased risk of breast cancer, and that some increased risk persists for more than a decade after use stops. The findings, published in The Lancet, suggest that all types of MHT, except topical vaginal oestrogens, are associated with increased risks of breast cancer.
See original article at: https://www.eurekalert.org/pub_releases/2019-08/tl-pss082719.php
